Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

Official title

Efficacy, Safety, and Tolerability of Switching to a Two-Drug Regimen With DTG/3TC Compared to Maintaining a Three-Drug Regimen With BIC/FTC/TAF or DTG/3TC/ABC in Virologically Suppressed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

Overview

This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged ≥18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained virological suppression (HIV-1 RNA \<50 copies/mL) for at least 48 weeks. Participants will be randomized in a 2:1 ratio: 104 to switch to DTG/3TC and 52 to continue their current regimen (control group).

Detailed description

Since the identification of the human immunodeficiency virus (HIV), developing effective, safe, and well-tolerated antiretroviral therapy (ART) for people living with HIV (PLWH) has been a global health priority. Advances in ART have significantly improved the prognosis for PLWH, achieving life expectancies comparable to the general population. However, three-drug regimens, such as bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine/abacavir (DTG/3TC/ABC), are associated with metabolic, renal, and cardiovascular adverse effects, particularly in the Mexican population, which has a high prevalence of metabolic syndrome.

Clinical trials, including GEMINI, TANGO, SALSA, RUMBA, PASO DOBLE, and DYAD, have demonstrated that two-drug regimens, such as dolutegravir/lamivudine (DTG/3TC), offer comparable virological efficacy and improved tolerability. Reducing the pharmacological burden may minimize adverse effects while maintaining viral suppression. The impact of metabolic disturbances on fat weight gain remains a controversial issue.

Objectives General Objective To compare the effectiveness, safety, and tolerability of switching to a DTG/3TC regimen versus continuing BIC/FTC/TAF or DTG/3TC/ABC in virally suppressed PLWH at 24 and 48 weeks of treatment.

Secondary Objectives

* Assess changes in lipid profile, body mass index (BMI), and abdominal circumference. * Evaluate alterations in glucose metabolism. * Measure changes in blood pressure and cardiovascular risk using Framingham and AHA/ACC scales. * Analyze changes in body composition (fat, water, muscle). * Document adverse events associated with ART. Study Design This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged ≥18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained virological suppression (HIV-1 RNA \<50 copies/mL) for at least 48 weeks. Participants will be randomized in a 2:1 ratio: 104 to switch to DTG/3TC and 52 to continue their current regimen (control group).

Inclusion Criteria

* Age ≥18 years. * Virological suppression (HIV-1 RNA \<50 copies/mL) for ≥48 weeks. * Estimated glomerular filtration rate (eGFR) ≥60 mL/min. * Signed informed consent. Exclusion Criteria * Pregnancy or breastfeeding. * Hepatitis B or C coinfection. * Active malignancy. * Use of recreational drugs or medications with significant interactions with ART.

Procedures Following approval by the local ethics committee, participant recruitment will commence. Participants will be followed continuously for 48 weeks. Data will be collected on efficacy (viral suppression), safety (adverse events), and tolerability (patient-reported outcomes and clinical assessments).

Data Management and Statistical Analysis

Patient data will remain confidential and accessible only to study investigators. Data will be recorded in an SPSS database. Statistical analyses will include:

* Kolmogorov-Smirnov test for normality. * χ² test for categorical variables. * Student's t-test or Mann-Whitney U test for continuous variables, as appropriate. * ANOVA for group comparisons. * Paired tests for within-group changes. A significance level of p ≤ 0.05 will be applied.

Feasibility The Hospital de Infectología, National Medical Center "La Raza," has the necessary infrastructure, trained personnel, and access to study medications to conduct this trial. The study is independent and not sponsored by any pharmaceutical company.

Interventions

• Drug Standard Medical Therapy
  Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet.
• Drug dual therapy
  Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs

Primary outcome measures

• Effectiveness. [Time frame: 24 and 48 weeks.]
• Safety of switching ART regimen with an INSTI to DTG/3TC. [Time frame: 24 and 48 weeks.]
• Tolerability of switching ART regimen with an INSTI to DTG/3TC. [Time frame: 24 and 48 weeks.]

Secondary outcome measures (6)

• Changes in lipid profile. [Time frame: 24 and 48 weeks]
• Changes in body mass index [Time frame: 24 and 48 weeks.]
• Changes in waist circumference. [Time frame: 24 and 48 weeks.]
• Glucose metabolism disorders. [Time frame: 24 and 48 weeks.]
• Assess changes in blood pressure and cardiovascular risk [Time frame: 24 and 48 weeks]
• Measure body composition [Time frame: 24 and 48 weeks]

Eligibility criteria

Inclusion criteria

• PLWH aged over 18 years.
• Virologically suppressed for at least 48 weeks prior to study enrollment.
• On ART with Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) or Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC).
• No history of virologic failure.
• Willing to participate in the study.
• Signed written informed consent.
• HIV-1 RNA <50 copies/mL within 4 weeks prior to randomization.
• eGFR by CKD-EPI ≥60 mL/min.

Exclusion criteria

• Pregnant or breastfeeding patients.
• Known allergies to any component of the antiretroviral regimens.
• Coinfection with hepatitis B and/or hepatitis C virus.
• Concomitant medications that interact with any component of the ART regimens.
• Diagnosis of malignancy prior to randomization.
• Use of recreational drugs with anorexigenic potential (crystal meth, methamphetamines, cocaine) within 60 days prior to randomization.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Mexico · 1 center

• Hospital de Infectología, Centro Médico Nacional La Raza — Mexico City

Publications

• Rolle CP, Castano J, Nguyen V, Hinestrosa F, DeJesus E. Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study. Open Forum Infect Dis. 2024 Sep 26;11(10):ofae560. doi: 10.1093/ofid/ofae560. eCollection 2024 Oct. PMID 39416993
• Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week PMID 35235656
• De Scheerder MA, Degroote S, Delporte M, Kiselinova M, Trypsteen W, Vincke L, De Smet E, Van Den Eeckhout B, Schrooyen L, Verschoore M, Muccini C, Vanherrewege S, Caluwe E, De Buyser S, Gerlo S, Blomme E, Vandekerckhove L. In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA). J Infect Dis. 2025 F PMID 39226296
• van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults PMID 31905383

Identifiers

NCT: NCT07138144 · R-2025-3502-186

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗